Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1417 • 2013 ACR/ARHP Annual Meeting
Lack Of Correlation Between Golimumab Exposure and Selected Safety Events Following Intravenous Or Subcutaneous Administration In An Integrated Analysis Of Phase 3 Data Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis
Jocelyn H. Leu¹, Anna Beutler¹, Alan M. Mendelsohn², Sam Liao³, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA, ³PharMax Research, Inc., Newport Beach, CA
Background/Purpose: For anti-TNFα agents, infections and malignancies are key safety concerns. It is unknown whether safety events are driven by peak (Cmax), trough (Cmin), average…
Abstract Number: 385 • 2013 ACR/ARHP Annual Meeting
Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention
Silvia Rollefstad¹, Eirik Ikdahl², Tore K. Kvien^3,4, Terje R. Pedersen^4,5, Ingar Holme⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, ⁶Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV)…
Abstract Number: 2491 • 2013 ACR/ARHP Annual Meeting
Serum Levels Of Novel Noggin- and Sclerostin-Immune Complexes Are Elevated In Ankylosing Spondylitis
Florence W. Tsui¹, Hing Wo Tsui² and Robert D. Inman³, ¹Genetics and Development / Immunology, Toronto Western Research Institute UHN and University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute UHN, Toronto, ON, Canada, ³Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Unravelling the basis of joint inflammation and ankylosis represents a major challenge in ankylosing spondylitis (AS) research. As noggin (NOG) and sclerostin (SOST) have…
Abstract Number: 2160 • 2013 ACR/ARHP Annual Meeting
The Journey to Diagnosis in As/Axial Spondyloarthritis – the Psychological Impact of Delay
Jane Martindale^1,2 and Lynne Goodacre², ¹Physiotherapy, Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom, ²Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
Background/Purpose: It is not uncommon for 8 to 11 years to pass between symptoms onset and definitive diagnosis of AS/axial SpA (Gran 1997, Feldtkeller, 2003).…
Abstract Number: 1552 • 2013 ACR/ARHP Annual Meeting
Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel³, Christian Althoff⁴, Denis Poddubnyy³, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration of
Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting
Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
Abstract Number: 332 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)
Zohair Abbas¹ and Marina N. Magrey², ¹Rheumatology, Case Western Reserve University at Metrohealth Medical Center, Cleveland, OH, ²Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Both patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at increased risk of cardiovascular disease (CVD). This increased risk is in part…
Abstract Number: 2225 • 2012 ACR/ARHP Annual Meeting
Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)
Dominique L. Baeten¹, Stephan Bek², Jiawei Wei³, Arndt Brachat⁴, Joachim Sieper⁵, Paul Emery⁶, Jürgen Braun⁷, Desiree M. van der Heijde⁸, Iain B. McInnes⁹, Jacob M. van Laar¹⁰, R. Landewe¹¹, Paul Wordsworth¹², Jurgen Wollenhaupt¹³, Herbert Kellner¹⁴, Jacqueline E. Paramarta¹⁵, Arthur Bertolino¹⁶, Andrew Wright¹⁷ and Hueber Wolfgang², ¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Integrated Information Sciences (IIS), Beijing Novartis Pharma Co. Ltd., Shanghai,, China, ⁴Novartis Pharma AG, Novartis Pharma AG, Basel, Switzerland, ⁵Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁶Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹⁰Newcastle University, Musculoskeletal Research Group, Newcastle, United Kingdom, ¹¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹²Nuffield Orthopaedic Centre, Oxford, United Kingdom, ¹³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁴Centre for Inflammatory Joint Diseases, Munich, Germany, ¹⁵Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹⁶Translational Medicine- 3rd Floor, Novartis Institutes for BioMedical Research, Basel, Switzerland, ¹⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab has shown to be well tolerated and effective in active ankylosing spondylitis (AS) patients in a proof-of-concept trial1. Briefly, at Week (Wk) 6,…
Abstract Number: 1383 • 2012 ACR/ARHP Annual Meeting
The Burden of Ankylosing Spondylitis and the Cost-Effectiveness of Anti-Tumor Necrosis Factor α Agents in Romania
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Ankylosing Spondylitis (AS) usually affects young males, severely impairing their quality of life. Chronic treatment of AS using anti-TNF α agents is costly and…
Abstract Number: 592 • 2012 ACR/ARHP Annual Meeting
Two Novel Diagnostic Biomarkers of Cartilage Degradation and Connective Tissue Inflammation Are Predictive of Disease Progression in Ankylosing Spondylitis
Anne C. Bay-Jensen¹, Stephanie Wichuk², Inger Byrjalsen³, Zheng Zhao⁴, Robert GW Lambert⁵, Morten Asser Karsdal⁶ and Walter P. Maksymowych⁷, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁵Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Nordic Bioscience A/S, Herlev, Denmark, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Cartilage degradation and inflammation of synovial and connective tissue are key events in inflammatory arthropathies such as SpA. Presently there are no prognostic tools…
Abstract Number: 2652 • 2012 ACR/ARHP Annual Meeting
Benefits of Aerobic Training in Patients with Ankylosing Spondylitis Are Not Coupled by Effects On Cytokines: A Randomized Controlled Trial
Fabio Jennings¹, Hilda A. Oliveira², Marcelo C. Sousa¹, Vaneska G. Cruz¹, Fabio S. Lira³ and Jamil Natour¹, ¹Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Psicobiology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Ankylosing Spondylitis (AS) is a systemic inflammatory disease that causes deterioration of physical capacity. Although exercises remain essential in the treatment, the literature lacks…
Abstract Number: 2233 • 2012 ACR/ARHP Annual Meeting
Assessing the Clinical and Economic Burden of U.S. Veteran Ankylosing Spondylitis Patients
Lin Xie¹, Onur Baser², Ahong Huang³, Lu Li³, Elyse K. Fritschel³ and Li Wang⁴, ¹Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI, ²President/Adjunct Professor of Internal Medicine, STATinMED Research/The University of Michigan, Ann Arbor, MI, ³STATinMED Research, Dallas, TX, ⁴Director, Analytic Research, STATinMED Research, Dallas, TX
Background/Purpose: To examine the economic burden, demographic and clinical characteristics of ankylosing spondylitis (AS) in the U.S. veteran population. Methods: A retrospective database analysis…
Abstract Number: 1384 • 2012 ACR/ARHP Annual Meeting
The Frequency of Non-Radiographic Axial Spondyloarthritis in Relation to Symptom Duration in Patients Referred Because of Chronic Back Pain: Results From the Berlin Early Spondyloarthritis Clinic
Denis Poddubnyy¹, Henning Brandt², Janis Vahldiek³, Inge Spiller², In-Ho Song⁴, Martin Rudwaleit⁵ and Joachim Sieper⁶, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Medical Department I, Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, ³Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, ⁴Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ⁵Endokrinologikum Berlin, Berlin, Germany, ⁶Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axial SpA (=ankylosing spondylitis – AS) are considered currently as two stages of axial SpA. We reported recently…
Abstract Number: 597 • 2012 ACR/ARHP Annual Meeting
Investigating the Genetic Association Between ERAP1 and Spondyloarthritis
Amir Kadi¹, Brigitte Izac², Roula Said-Nahal³, Ariane Leboime⁴, Kurt L. de Vlam⁵, Dirk Elewaut⁶, Gilles Chiocchia² and Maxime A. Breban³, ¹Institut Cochin - Université Paris Descartes - INSERM U1016 - CNRS (UMR 8104), Paris, France, ²Immunology and Hematology Department, Institut Cochin - INSERM U1016 - CNRS (UMR 8104), Paris, France, ³Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁴Rheumatology Division, Ambroise-Paré Hospital AP-HP, Boulogne-Billancourt, France, ⁵Rheumatology, University Hospitals Leuven, Leuven, Belgium, ⁶Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose: A robust association was recently identified between polymorphisms in the non-major histocompatibility complex gene ERAP1 and ankylosing spondylitis (AS) in several populations. The aim…
Abstract Number: 2235 • 2012 ACR/ARHP Annual Meeting
How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters
Xenofon Baraliakos¹, Claudia Fritz², Joachim Listing³, Hildrun Haibel⁴, Joachim Sieper⁵ and Jürgen Braun⁶, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ⁵Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁶PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: Measures for disease activity (BASDAI) or response to therapy (ASAS partial remission (PR)) are widely used in the assessment of patients with ankylosing spondylitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].